NHS waiting lists for gender care in the UK now run to several years, leaving many trans people and families weighing private clinics, shared care arrangements, and other routes. Understanding what each pathway involves, what it costs, and how to stay safe in the meantime is the practical knowledge that makes the difference.
Why are NHS waits so long, and what does that mean in practice?
The NHS has always had limited capacity for gender-related care, and political pressure over recent years has narrowed that capacity further rather than expanding it. For adults, referral to a gender clinic and a first appointment can now mean a wait of several years. For young people under 18, the picture shifted dramatically when the Tavistock clinic's Gender Identity Development Service closed; NHS provision for children and young people is being rebuilt from scratch through a regional hub model, and the waits during that transition have been severe.
What this means practically is that a young person referred today may reach 18 before they are seen. An adult in their twenties may spend the better part of their late twenties waiting. For many people, the NHS pathway is functionally inaccessible in any timely sense, and the question becomes not whether to wait but what to do while waiting, or instead.
What are the main alternatives to the NHS while you wait?
There are broadly three routes people take: a regulated private clinic in the UK, an overseas provider offering remote consultation, or obtaining hormones independently without clinical oversight. Each carries different levels of cost, safety, access, and risk.
UK private gender clinics
A regulated UK private clinic can assess, prescribe, and monitor gender-affirming hormone therapy (HRT) without the NHS wait. The standard of care at reputable providers follows the same international guidelines that underpin good gender medicine globally: informed consent, hormone monitoring through blood tests, and dose adjustment over time. Assessment timescales at private providers are typically weeks rather than years.
The costs are real and worth knowing in advance. An initial assessment appointment, blood tests, and a first prescription can run to several hundred pounds, and ongoing consultations and monitoring add to that. If the clinic writes to your GP and the GP agrees to take over prescribing under a shared care arrangement (more on that below), the ongoing medication costs can drop significantly, because NHS prescriptions are far cheaper than private ones. Not every clinic is equally good at supporting this handover, so it is worth asking about it before you commit.
Overseas and remote providers
Some providers operate from outside the UK and offer remote consultations, prescribing medications that are then sourced privately. These vary enormously in quality. Some follow rigorous international standards; others do not. The challenge is that if something goes wrong, recourse is limited, and your GP is unlikely to engage in shared care with a provider they cannot verify. If cost is the primary driver and a UK private clinic is out of reach financially, this route is worth researching carefully rather than ruling out entirely, but knowing what to look for in a provider matters.
GenderGP at gendergp.com operates as a remote provider with a track record in gender-affirming care and an established process for working with people who are waiting for NHS access. It is the service I point people to when they need to actually start, continue, or change treatment.
DIY hormone therapy
DIY means sourcing hormones without clinical oversight, typically through online pharmacies operating in other jurisdictions. People do this, and often the reason is straightforwardly that every other route has been too slow, too expensive, or too inaccessible. But the risks are specific and worth naming plainly: without monitoring, it is impossible to know whether doses are appropriate, whether levels are within a safe range, or whether any early warning signs in blood results are being caught. Oestrogen therapy carries a dose-related risk of blood clots; testosterone therapy requires monitoring of haematocrit (red blood cell concentration) and liver function, among other things.
If someone is going to pursue this route regardless, harm reduction matters. That means knowing how to order reputable private blood tests (many are available online without a GP), understanding which results to look at and what the ranges mean, knowing the signs that something needs urgent attention, and keeping a GP informed if at all possible. A GP who knows a patient is on hormones can monitor them even without prescribing, and that monitoring is genuinely valuable.
How does shared care work, and how do you get a GP to agree?
Shared care is the arrangement where a private or remote specialist does the assessment and initial prescribing, and the GP then takes on day-to-day prescribing and blood test monitoring. When it works, it is the most practical and affordable ongoing arrangement for most people.
Getting a GP to agree is not guaranteed, and it is not a simple ask. Some GP practices have a standing policy of accepting shared care letters from private gender specialists; others decline on principle. Some individual GPs are warm and knowledgeable about gender care; others are not. The conversation goes better when the specialist provides a clear, detailed shared care letter that sets out exactly what monitoring is needed, what dose has been agreed, and what the clinical rationale is. If the GP declines, they should explain why, and that reason can sometimes be challenged or worked around.
If your GP is refusing to prescribe or monitor medication that has been started safely by a qualified specialist, that is worth taking further. NHS England published guidance on shared care for gender-affirming hormones, and a GP declining without good clinical reason is in a difficult position given that guidance. Putting the request in writing and asking for a written reason for refusal is a useful step.
What about children and young people specifically?
The situation for under-18s is more constrained in the UK than it is for adults, and it has become more constrained over recent years. Puberty blockers, which pause the physical changes of puberty to give a young person and their family more time to think without irreversible changes accumulating, are effectively unavailable on the NHS for gender-questioning young people at present, and private prescription has been banned in the UK. This ban has caused real harm to trans young people whose access to timely care has been removed.
For young people approaching 18 or those whose parents want to plan ahead, the picture shifts somewhat: cross-sex hormones (oestrogen for trans girls, testosterone for trans boys) can be accessed through some private providers once a young person is 16, and in some cases earlier with parental involvement and appropriate specialist assessment. What this means in practice is that for many families, the focus during a long NHS wait becomes preparation: understanding what care will look like, getting assessments done privately if possible, building a relationship with a knowledgeable GP, and ensuring the young person has support.
The harm of delay is not abstract. Unwanted puberty changes are distressing, many are permanent, and the dysphoria that accumulates during an untreated wait has real consequences for mental health and wellbeing. Acknowledging that is not alarmism; it is basic clinical honesty. Delay is never neutral.
What questions should you ask a private provider before you start?
Not every private provider is equally good, so these are the things worth finding out before committing time and money. Do they follow an established international standard of care? Do they provide a shared care letter for your GP, and do they have experience supporting GPs through that process? How do they handle monitoring, and will they help you interpret results? What happens if something goes wrong or if you have a concern between appointments? What are the full costs, including follow-up? Are prescribers registered and verifiable with a UK regulatory body or an equivalent body in their jurisdiction?
Good providers answer these questions clearly and without defensiveness. If the answers are vague or the provider seems reluctant to explain their clinical process, that is worth taking seriously.
What about the emotional side of waiting?
People often tell me that the waiting itself is a form of harm, separate from the physical effects of delayed treatment. Knowing that the care you need exists, that other people are accessing it, and that the only barrier is a bureaucratic queue is genuinely difficult. That is not a weakness; it is a rational response to an unreasonable situation.
Support during a wait matters. Whether that is a gender-aware therapist, an online community of people in similar situations, a school counsellor who gets it, or a GP who is willing to monitor and advocate even without specialist input, connection to someone who understands makes the wait more survivable. For parents, finding other families navigating the same path is often the thing that makes the most difference.
If there is a topic that you would like me to cover, just let Sammy know.
Dr Helen Webberley is a gender specialist, medical educator, and advocate. She is the founder of GenderGP and writes about gender diversity, trans healthcare, and the lives around them.
Comments